Sight Sciences Reports Record Q3 2026 Revenue and Raises Full Year Guidance
Sight Sciences (SGHT) reported strong third-quarter results for 2026, highlighted by total revenue of $24.9 million, a 25% increase year-over-year. The company's growth was driven by both its Interventional Glaucoma (IG) segment, which reached $21.0 million in revenue, and significant momentum in the Interventional Dry Eye (IDE) segment, which saw a 45% sequential increase to $3.9 million. Following these results, management raised its full-year 2026 revenue guidance to a range of $92 million to $93 million. The company also demonstrated improved operational efficiency, reporting a net loss of $6.8 million—a 17% improvement over the previous year—and a significant reduction in quarterly cash usage. Strategic expansions in payer coverage through Aetna are expected to support continued adoption of its OMNI and TearCare products.
Tickers: $SGHT
Topics: gross margin guidance raise revenue growth segment performance